Free shipping on all orders over $ 500

BGT226 maleate

Cat. No. M1735

All AbMole products are for research use only, cannot be used for human consumption.

BGT226 maleate Structure
Synonym:

NVP-BGT226

Size Price Availability Quantity
1mg USD 50  USD50 In stock
5mg USD 120  USD120 In stock
10mg USD 195  USD195 In stock
25mg USD 400  USD400 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

BGT226 (NVP-BGT226) is a novel phosphoinositide 3-kinase/mTOR dual inhibitor. BGT226 (NVP-BGT226) displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.

Protocol (for reference only)
Cell Experiment
Cell lines FaDu, Detroit 562, HONE-1 and HONE-1-C15 cells line
Preparation method Growth-inhibition assay.
Cells in the logarithmic growth phase were cultured at a density of 5,000 to 20,000 cells per milliliter per well in a 24-well plate. The cells were exposed to various concentrations of BGT226 for 3 generation times. At the end of the incubation period, cells were fixed and stained with 50% ethanol containing 0.5% methylene blue for 30 minutes. The resulting colored residues were dissolved in 1% N-lauroyl-sarcosine, and optical density was read at 550 nm using a microplate reader. The IC50 value resulting from 50% inhibition of cell growth was calculated graphically as a comparison with control groups. Each point represents the average of at least 3 independent experiments run in duplicate.
Concentrations IC50 ranging from 7.4 to 30.1 nmol/L
Incubation time 48 h
Animal Experiment
Animal models human FaDu xenografted mice
Formulation dissolved in 90% N-methyl-2-pyrrolidone (NMP)/10% PEG300
Dosages 3.5 and 5mg/kg once a day for 21 consecutive days
Administration orally
Chemical Information
Molecular Weight 650.6
Formula C32H29F3N6O6
CAS Number 1245537-68-1
Form Solid
Solubility (25°C) DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Markman et al. Ann Oncol. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.

[2] Glienke et al. Tumour Biol. The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines.

[3] Chang KY, et al. Clin Cancer Res. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.

[4] Baumann et al. Anticancer Drugs. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma.

Related PI3K Products
PI3Kγ inhibitor AZ2 

PI3Kγ inhibitor AZ2 is a highly selective PI3Kγ inhibitor (The pIC50 value for PI3Kγ is 9.3).

NIBR-17 

NIBR-17 is a pan-class I PI3K inhibitor with suitable pharmacokinetic properties and inhibits tumor growth.

RV-1729 

RV-1729 is an inhibitor of the phosphatidylinositol 3-kinase-δ (PI3Kδ).

Vulolisib 

Vulolisib is a potent and orally active phosphatidylinositol 3-kinase (PI3K) inhibitor, with IC50 values of 0.2 nM, 168 nM, 90 nM and 49 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively.

Vps34-IN-4 

Vps34-IN-4 is a potent, selective, and orally active inhibitor of VPS34.

  Catalog
Abmole Inhibitor Catalog




Keywords: BGT226 maleate, NVP-BGT226 supplier, PI3K, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.